Publication | Closed Access

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients

UrologyMedicinePhase IiiPharmacologyPharmacotherapyMulticenter TrialCancer TreatmentProstatic DiseaseOncologyJapanese Patients